News | February 08, 2022
GlaxoSmithKline Pharmaceuticals delivers strong financials in Q3FY22
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
EBITDA from Continuing Operations at Rs. 582 crore recorded a growth of 31 %.
Granules India has reported consolidated financial results for the period ended December 31, 2021
Key takeaways of recent quarter & conference call highlights
Sun Pharma’s Q3FY22 operational performance was in line with I-direct estimates with sustained momentum and good growth across businesses
The pharma division’s domestic business generated turnover of Rs. 219.85 crore for the last financial year
ICICI Direct analysis of Dr Reddy’s Q3FY22 results
ICICI Direct’s analysis of Cipla’s Q3FY22 results
Sun Pharmaceutical Industries has reported consolidated financial results for the period ended December 31, 2021
The management guided for ARV API & formulation demand to be normalised from Q4FY22 and reiterated the aspiration of US $ 1 billion in sales by FY23: ICICI Direct
Cipla announced its unaudited consolidated financial results for quarter ended December 31st, 2021.
Subscribe To Our Newsletter & Stay Updated
